This site uses cookies, including third-party cookies, that help us to provide and improve our services. Privacy Policy

Liver Cancer Diagnostics Market

Liver Cancer Diagnostics Market

Liver Cancer Diagnostics Market By Test Type (AFP Tests for Liver Cancer Diagnostics, LFTs for Liver Cancer Diagnostics, Biopsy for Liver Cancer Diagnostics), By End-User (Hospital-associated Labs, Independent Diagnostic Laboratories,Cancer Research Institutes) & Regional Forecast, 2021-2031

Liver Cancer Diagnostics Market
  • Oct-2021
  • List of Tables : 165
  • List of Figures : 51
  • 170 Pages
  • Healthcare

Liver Cancer Diagnostics Market Outlook

This revised research analysis on the liver cancer market by skilled analysts at Fact.MR predicts the industry to expand at a healthy CAGR of 8.2% over the next ten years.

CAGR (2021-2031) 8.2%
North America Market Share 35%
Global Market Value by 2031 US$ 22 Bn
Global Market Value in 2020 US$ 10 Bn

Fact.MR, a market research and competitive intelligence provider, offers in-depth insights on aspects such as risks, opportunities, growth drivers, restraints, etc. The global liver cancer diagnostics market was found to be worth US$ 10 Bn in 2020, and is expected to expand 2X by the end of 2031.

Interested to Procure The Data

Demand Analysis of Liver Cancer Diagnostics (2016 to 2020) Vs Market Projections (2021 to 2031)

Instances of cancer have seen a substantial rise over the past decade, and this rise is expected to be seen through this decade as well. Liver cancer cases have seen a gradual increase as the lifestyle of people has changed drastically over the years. Prevalence of obesity due to poor eating habits is one of the major factors responsible for increase in liver cancer across the world.

Rising consumption of tobacco and alcohol is also a major lifestyle change that has promoted the disease, in turn, giving rise to more demand for effective liver cancer diagnostics. Hepatocellular carcinoma (HCC) diagnostics and liver carcinoma diagnostics are two major diagnostic methods that are in demand and expected to be prominent over the decade.

Demand for liver cancer diagnostics is anticipated to rise at a robust CAGR of 8.2% over 2021 to 2031 forecast period.

Which Technologies Related to Liver Cancer Diagnostics are Popular?

Research & development of new and advanced diagnostic solutions is always ongoing, and this is true for liver cancer diagnostic solutions as well. Innovations in liver cancer diagnostic procedures have been emerging and are expected to get only better over the next ten years.

Some of the new technologies are:

  • Fluorescent In Situ Hybridization (FISH) Technology for Liver Cancer Diagnostics
  • Comparative Genomic Hybridization (CGH) Technology for Liver Cancer Diagnostics
  • Immunohistochemical (IHC) Technology for Liver Cancer Diagnostics

An Adaptive Approach to Modern-day Research Needs

What Role Does Imaging Play in Liver Cancer Diagnostics?

Imaging plays a vital role in cancer diagnosis, as it allows medical professionals to explore the extent of tumors and their nature. Imaging for liver cancer diagnostics is also a very popular diagnostic method, and there is a wide array of imaging technologies and techniques to choose from.

Some of the imaging technologies and techniques are:

  • Endoscopy for Liver Cancer Diagnostics
  • Computed Tomography (CT) Scan for Liver Cancer Diagnostics
  • Magnetic Resonance Imaging (MRI) Scan for Liver Cancer Diagnostics
  • Ultrasound Imaging for Liver Cancer Diagnostics
  • MRI Imaging Tests for Liver Cancer Diagnostics
  • Laparoscopy Tests for Liver Cancer Diagnostics

Demand for imaging in liver cancer diagnostics is anticipated to be significant as imaging technology advances and becomes more accurate, efficient, and affordable. While there are some concerns regarding the constant use of imaging on the body, these constraints are expected to be ironed out as technology advances and research increases.

Demand for computed tomography (CT) scans in liver cancer diagnostics, demand for magnetic resonance imaging (MRI) scans in liver cancer diagnostics, demand for X-rays in liver cancer diagnostics, and demand for ultrasound imaging in liver cancer diagnostics are all expected to see similar growth as their adoption in various diagnostic procedures is developed.

Increase in demand for liver cancer diagnostic procedures is also expected to drive demand for endoscopy in liver cancer diagnostics and demand for laparoscopy tests in liver cancer diagnostics as their application scope increases.

Why is Demand for Laboratory Tests in Liver Cancer Diagnostics High?

Laboratory tests for liver cancer diagnostics are many to choose from, and all of them indicate different aspects of cancer tumors. Lab tests aid in understanding and determining the causes and nature of cancer, and can be crucial in planning an effective treatment plan.

Blood tests for liver cancer diagnostics are the most common lab-based tests. Demand for AFP tests for liver cancer diagnostics is moderate, as these tests are mostly effective in determining the treatment for the disease. Demand for LFTs for liver cancer diagnostics is slightly higher than that of AFP tests, as they provide direct information on the condition of the liver.

Research is bolstering and pioneering new tests that make diagnosis more efficient, accurate, and affordable. Use of growth factors and receptors for liver cancer diagnostics, enzymes and isoenzymes biomarkers for liver cancer diagnostics, and molecular markers for liver cancer diagnostics are some major areas of research that show promise in the near future. As research progresses, we are expected to see rise in the application of these new methods and tests.

Avail customized purchase options for your needs

Which Regional Markets are More Lucrative for Liver Cancer Diagnostic Providers?

This research details the global liver cancer diagnostics landscape across regions such as North America, Latin America, Europe, APAC, and MEA.

North America is anticipated to dominate the market with around 35% global liver cancer diagnostics market share. Demand in Europe is predicted to rise at a steady pace over the decade. Both these regions will see high growth owing to rising adoption of advanced technology and increasing instances of liver cancer.

The APAC region is anticipated to experience the highest CAGR owing to the adoption of improved diagnostic procedures for liver carcinoma in countries such as India and China. Demand for liver cancer diagnostics in independent diagnostic laboratories in APAC is expected to see a major rise as the cost-effectiveness of diagnostic solutions increases. The MEA market is expected to witness a steady growth in demand for liver cancer diagnostics.

Liver cancer diagnostics market regional analysis by Fact.MR

Country-wise Analysis

What Makes the U.S. Liver Cancer Diagnostics Market a Hotspot?

The U.S. is a highly lucrative market for liver cancer diagnostics, and this can be associated with factors such as presence of prominent providers, rising prevalence of related diseases, early adoption of novel procedures, etc. Demand for liver cancer diagnostics in cancer research institutes is expected to see a rise as research in the nation picks up pace.

What is the Outlook for Manufacturers of Liver Cancer Diagnosis Instruments in China?

China is the second-largest economy in the world, and that makes it a huge market for almost everything. The nation has a rising medical tourism industry that is propelling demand for liver cancer diagnostics as well.

Sales of liver cancer diagnosis instruments are also expected to see a rise as the government is backing manufacturers with favorable funding initiatives. Manufacturers of liver cancer diagnostic instruments in China are also investing in the research & development of cost-effective solutions to boost their sales.

Category-wise Analysis

Why is Demand for Liver Cancer Diagnostics in Hospital-associated Labs Prominent?

Hospital-associated labs are expected to account for a majority of the revenue share in the global liver cancer diagnostics industry over the forecast period.

Increasing focus on procedures that require a medical surrounding and tests that require hospitalization, and increasing demand for biopsy for liver cancer diagnostics are some of the major factors that are propelling growth of hospital-associated labs in the market.

COVID-19 Pandemic Evaluation

The COVID-19 pandemic of 2020 completely changed the way healthcare was approached by governments and individuals as well. In the post-pandemic era, the world is expected to see some major changes to healthcare infrastructure, and these changes would be from the fundamental blocks that were believed to be strong and effective.

From diagnosis to treatment, all aspects are expected to see major reforms with application of AI and other technological advancements to make them extremely effective. Research in the healthcare domain is being bolstered to create more effective diagnostics and treatment solutions, and the liver cancer diagnostics sector is also anticipated to follow a similar path.

Competitive Landscape

Top manufacturers of liver cancer diagnosis instruments are investing in research & development that would aid in diagnosis and treatment more effectively and efficiently.

  • In September 2021, India-based BDR Pharma announced the launch of the generic cancer drug called Cabozantinib. The drug is said to be helpful in the treatment of hepatocellular carcinoma and other types of cancers.
  • Adaptimmune and Genetech have announced a collaboration through which they would be commercializing allogeneic T-cell therapies to treat various cancers. This collaboration could generate around US$ 3 Bn for the companies involved.
  • In August 2021, 111, a digital health platform, entered into a strategic cooperation agreement with Suzhou Zelgen Biopharmaceuticals Co. to develop a virtual platform for liver cancer-affected individuals. The platform would provide patients access to online doctor consultations and medicines.

Liver Cancer Diagnostics Industry Report Scope

Attribute Details
Forecast Period 2021-2031
Historical Data Available for 2016-2020
Market Analysis Units for Volume and US$ Mn for Value
Key Regions Covered
  • North America
  • Latin America
  • Europe
  • APEJ
  • MEA
Key Countries Covered
  • United States
  • Canada
  • Brazil
  • Mexico
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • China
  • Japan
  • South Korea
  • India
  • Indonesia
  • Malaysia
  • Singapore
  • Australia
  • New Zealand
  • Turkey
  • South Africa
  • and GCC Countries
Key Market Segments Covered
  • Test Type
  • End User
  • Region
Key Companies Profiled
  • Illumina Inc.
  • Foundation Medicine Inc.
  • Danaher Corporation
  • Sysmex Corporation
  • Biocept Inc.
Pricing Available upon Request

Key Segments Covered in Liver Cancer Diagnostics Industry Survey

  • By Test Type:

    • AFP Tests for Liver Cancer Diagnostics
    • LFTs for Liver Cancer Diagnostics
    • Biopsy for Liver Cancer Diagnostics
    • Others
  • By End User:

    • Hospital-associated Labs
    • Independent Diagnostic Laboratories
    • Cancer Research Institutes
    • Others

- FAQs -

North America is anticipated to dominate the global industry in terms of revenue with 35% market share.

Illumina Inc., Foundation Medicine Inc., Danaher Corporation Sysmex Corporation, and Biocept Inc. are key players profiled in this survey.

Hospital-associated labs are expected to account for majority of revenue share.

Rising prevalence of obesity & diabetes and increasing consumption of tobacco & alcohol are surging cancer cases, and thereby demand for liver cancer diagnostics.

Liver cancer diagnostics market growth through 2031 is anticipated to be at a CAGR of 8.2%.

Sales revenue from liver cancer diagnostics totaled nearly US$ 10 Bn in 2020.

Demand for MRI imaging tests for liver cancer diagnostics and CT scans is prominent in this marketplace.

By 2031, the global market for liver cancer diagnostics is estimated to be worth around US$ 22 Bn.

Need an Exclusive Report for your Unique Requirement?

- Related Reports -

Lung Cancer Diagnostics Market

The lung cancer diagnostics market revenue to reach US$ 4 Bn by 2031, cultivating CAGR of 7%. Hospit...

Paper Diagnostics Market

Paper Diagnostics Market expects a healthy 8.1% CAGR growth during 2021-2031. Rise in COVID-19 cases...

Electromagnetic Navigation Bronchoscopy Market

Electromagnetic navigation bronchoscopy to cost approximately US$ 3,000 per biopsy as compared to CT...

Blood Cancer Diagnostics Market

Blood cancer diagnostics Market is anticipated to register CAGR growth at 6% during 2021-2031. Indep...

- Our Clients -

Report Client

- Evaluate How Fact.MR's Report Can Help. -

Is the market research conducted by Fact.MR?

Yes, the report has been compiled by expert analysts of Fact.MR, through a combination of primary and secondary research. To know more about how the research was conducted, you can speak to a research analyst.

What research methodology is followed by Fact.MR?

Fact.MR follows a methodology that encompasses the demand-side assessment of the market, and triangulates the same through a supply-side analysis. This methodology is based on the use of standard market structure, methods, and definitions.

What are the sources of secondary research?

Fact.MR conducts extensive secondary research through proprietary databases, paid databases, and information available in the public domain. We refer to industry associations, company press releases, annual reports, investor presentations, and research papers. More information about desk research is available upon request.

Who are the respondents for primary research?

Fact.MR speaks to stakeholders across the spectrum, including C-level executives, distributors, product manufacturers, and industry experts. For a full list of primary respondents, please reach out to us.

Is a sample of this report available for evaluation?

Yes, you can request a sample, and it will be sent to you through an email.